KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Acquisitions (2018 - 2021)

Historic Acquisitions for Takeda Pharmaceutical (TAK) over the last 4 years, with Q4 2021 value amounting to -$194.6 million.

  • Takeda Pharmaceutical's Acquisitions changed N/A to -$194.6 million in Q4 2021 from the same period last year, while for Mar 2022 it was -$446.3 million, marking a year-over-year change of. This contributed to the annual value of -$442.4 million for FY2022, which is N/A changed from last year.
  • Takeda Pharmaceutical's Acquisitions amounted to -$194.6 million in Q4 2021.
  • Takeda Pharmaceutical's 5-year Acquisitions high stood at $652350.5 for Q3 2019, and its period low was -$26.3 billion during Q1 2019.
  • For the 4-year period, Takeda Pharmaceutical's Acquisitions averaged around -$3.0 billion, with its median value being -$60.9 million (2018).
  • Examining YoY changes over the last 5 years, Takeda Pharmaceutical's Acquisitions showed a top increase of 10107.18% in 2019 and a maximum decrease of 9231.18% in 2019.
  • Over the past 4 years, Takeda Pharmaceutical's Acquisitions (Quarter) stood at -$60.9 million in 2018, then surged by 99.85% to -$92014.2 in 2019, then plummeted by 2894.47% to -$2.8 million in 2020, then plummeted by 6963.45% to -$194.6 million in 2021.
  • Its Acquisitions stands at -$194.6 million for Q4 2021, versus -$251.7 million for Q2 2021 and -$2.8 million for Q1 2020.